In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread

Treatments for Clostridium difficile infection remain limited, despite the introduction of fidaxomicin, and development of new agents is necessary. We determined the in vitro susceptibilities of 199 prevalent or emerging Clostridium difficile PCR ribotypes to MCB3681, a novel investigational quinolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Freeman, Jane, Pilling, Sally, Vernon, Jonathan, Wilcox, Mark H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2017
Materias:
Susceptibility
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328556/
https://www.ncbi.nlm.nih.gov/pubmed/27993853
http://dx.doi.org/10.1128/AAC.02077-16
_version_ 1782510910542184448
author Freeman, Jane
Pilling, Sally
Vernon, Jonathan
Wilcox, Mark H.
author_facet Freeman, Jane
Pilling, Sally
Vernon, Jonathan
Wilcox, Mark H.
author_sort Freeman, Jane
collection PubMed
description Treatments for Clostridium difficile infection remain limited, despite the introduction of fidaxomicin, and development of new agents is necessary. We determined the in vitro susceptibilities of 199 prevalent or emerging Clostridium difficile PCR ribotypes to MCB3681, a novel investigational quinolonyl-oxazolidinone, and 8 comparators (metronidazole, vancomycin, fidaxomicin, moxifloxacin, ciprofloxacin, clindamycin, tigecycline, and linezolid). MCB3681 showed good activity against C. difficile with no evidence of MCB3681 resistance in isolates showing either moxifloxacin or linezolid resistance or both moxifloxacin and linezolid resistance.
format Online
Article
Text
id pubmed-5328556
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-53285562017-03-09 In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread Freeman, Jane Pilling, Sally Vernon, Jonathan Wilcox, Mark H. Antimicrob Agents Chemother Susceptibility Treatments for Clostridium difficile infection remain limited, despite the introduction of fidaxomicin, and development of new agents is necessary. We determined the in vitro susceptibilities of 199 prevalent or emerging Clostridium difficile PCR ribotypes to MCB3681, a novel investigational quinolonyl-oxazolidinone, and 8 comparators (metronidazole, vancomycin, fidaxomicin, moxifloxacin, ciprofloxacin, clindamycin, tigecycline, and linezolid). MCB3681 showed good activity against C. difficile with no evidence of MCB3681 resistance in isolates showing either moxifloxacin or linezolid resistance or both moxifloxacin and linezolid resistance. American Society for Microbiology 2017-02-23 /pmc/articles/PMC5328556/ /pubmed/27993853 http://dx.doi.org/10.1128/AAC.02077-16 Text en Copyright © 2017 Freeman et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle Susceptibility
Freeman, Jane
Pilling, Sally
Vernon, Jonathan
Wilcox, Mark H.
In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread
title In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread
title_full In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread
title_fullStr In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread
title_full_unstemmed In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread
title_short In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread
title_sort in vitro activities of mcb3681 and eight comparators against clostridium difficile isolates with known ribotypes and diverse geographical spread
topic Susceptibility
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328556/
https://www.ncbi.nlm.nih.gov/pubmed/27993853
http://dx.doi.org/10.1128/AAC.02077-16
work_keys_str_mv AT freemanjane invitroactivitiesofmcb3681andeightcomparatorsagainstclostridiumdifficileisolateswithknownribotypesanddiversegeographicalspread
AT pillingsally invitroactivitiesofmcb3681andeightcomparatorsagainstclostridiumdifficileisolateswithknownribotypesanddiversegeographicalspread
AT vernonjonathan invitroactivitiesofmcb3681andeightcomparatorsagainstclostridiumdifficileisolateswithknownribotypesanddiversegeographicalspread
AT wilcoxmarkh invitroactivitiesofmcb3681andeightcomparatorsagainstclostridiumdifficileisolateswithknownribotypesanddiversegeographicalspread

Ejemplares similares